Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
2019 ◽
Vol 25
(16)
◽
pp. 4888-4897
◽
2017 ◽
Vol 35
(4)
◽
pp. 451-462
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 11010-11010
◽
2012 ◽
Vol 48
◽
pp. 191-192
◽
2017 ◽